Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vår Energi ASA: Notification of trade by primary insider

Sandnes, Norway, 22 August 2024: Chief Operating Officer, Torger Rød in Vår Energi has bought 10 000 shares in the company at a price of NOK 34.63 per share. Following the purchase, Torger Rød holds a total of 256 458 shares in Vår Energi ASA. This information is subject to the disclosure requirements pursuant to MAR article 19 and Section 5-12 the Norwegian Securities Trading Act. Contact Investor relations Ida Marie Fjellheim, Head of Investor Relations +47 90509291 ida.fjellheim@varenergi.no About Vår Energi Vår Energi is a leading independent upstream oil and gas

FlexQube is granted an additional patent for AMR Navigator

One additional patent application regarding FlexQube´s unique AMR system ("Autonomous Mobile Robot"), FlexQube Navigator, will be granted in the United States. The referred patent is of conceptual nature and is focusing on the principle to have a small and “non load carrying” AMR that navigates motorized load carriers through a standard coupling. Previously approved patents had a clear focus on the technology how to realize this principle, for example lifting up the AMR to make it non load carrying. The patent is a great complement to already approved patents and will give a strong

Form 8.3 - Britvic plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller ofinterests and shortpositions disclosed, ifdifferent from 1(a):     Thenaming of nominee or vehiclecompanies is insufficient. For a trust, the trustee(s),settlor and beneficiariesmust be named.(c) Name of offeror/offeree Britvic Plcin relation to whoserelevant

Spinomenal Releases Barnstorming Rooster Mayhem Slot

Leading iGaming content provider Spinomenal has released its barnstorming Rooster Mayhem slot, part of the popular Wildlife Series.Farm-inspired fun arrives in the form of a 5x3 slot game that features pigs, cows, sheep and goats as the medium symbols. Three or more Scattered Golden Egg symbols will trigger Free Spins. Players can win 10 Free Spins with three golden eggs, 15 Free Spins with four, and 20 Free Spins with five. Awaken the Wild Rooster within Free Spins and players will benefit from its ability to substitute for all other symbols except for the scattered Free Spins symbol.

GomSpace has to date received 24 MSEK in new product orders in Q3 2024

Since July 1, GomSpace has secured additional 24 MSEK in new product orders from customers globally, including earlier announced Unseenlabs products order announced on July 16.GomSpace products and subsystems will contribute to projects for 14 customers globally, including France, Spain, Korea, Kazakhstan, the UK, South Korea, Japan, Germany and Belgium. GomSpace Vice President of Products Business Unit, Henrik Kalstrup comments:”I am thrilled that our intensified emphasis on broadening our product sales has led to a notable growth in order intake for Products in the first half of Q3.

Net Asset Value(s)

Date: 22 August 2024 Global Opportunities Trust plc (the"Company") LEI: 2138005T5CT5ITZ7ZX58 Net Asset Values Global Opportunities Trust plc announcesthat the unaudited net asset values(NAVs) of the Company as at the close ofbusiness on 21 August 2024 are asfollows: 366.39 pence per share (including income)361.61 pence per share (excluding income)  For further information, please contact: Juniper Partners LimitedCompany Secretary0131 378 0500

Result of Meeting

22 August 2024       ChallengerX plc   (“ChallengerX”, “CX" or the "Company")   Results of General Meeting   ChallengerX , the trading company with principal activity of employing both traditional and non-traditional marketing strategies to rapidly “professionalise” amateur and semi-professional sports clubs around the world, announces that all resolutions were duly passed at the Company’s General Meeting held earlier today.   For further information, visit: https://challengerx.io/   The Directors of CX accept responsibility for this announcement.

Crypto All-Stars Raises $630,000 For Unified Meme Coin Staking, 100x ROI Possible Say Experts

The new meme coin Crypto All-Stars ($STARS)  is off to an exhilarating start in its presale, having already raised over $630,000in just its first week of launch.   The new project keeps the fire alive in the meme coin sector by offering its tokens a new utility: passive income generation via unified staking.   Crypto All-Stars introduces an industry-first capability. It allows the top meme coins in the space, such as Dogecoin ($DOGE) and Pepe ($PEPE), to be staked together, enabling their holders to earn a singular reward – the

Outokumpu – Announcement regarding change in holdings

Outokumpu CorporationStock exchange releaseAugust 22, 2024 at 2.00 pm EESTOutokumpu – Announcement regarding change in holdings Outokumpu Oyj (business identity code: 0215254-2) has on August 22, 2024 received a notification based on Chapter 9, Section 5 of the Finnish Securities Market Act. Varma Mutual Pension Insurance Company’s total holding in the shares and voting rights of Outokumpu has risen above 5% threshold and was 5.18% on August 21, 2024. Their earlier holding in the Outokumpu shares and voting rights was below minimum threshold. Total direct andindirect holdings

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt[®] technology to generate antibodies to a high-value target

Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt[®] technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties. Under this collaboration agreement, Oblique will partner with Lilly Catalyze360-ExploR&D, a

Half-year Report January - June 2024

· Net revenue from property management was SEK 1,049 million (1,004), an increase of 5 per cent. Including intra-Group rental revenue, net revenue from property management was SEK 1,147 million (1,101).   · Gross profit from property management increased by 4 per cent, totalling SEK 701 million (675). Including intra-Group rental revenue, gross profit from property management was SEK 799 million (771).   · Net result for the period was SEK -354 million (-1,372), equivalent to SEK -1.75 per share(-6.78). The negative result can be attributed to negative unrealised changes

Qt Group Plc Managers' Transactions Tuukka Turunen

Qt Group Plc, Stock exchange release, August 22, 2024, at 1:00PM EESTQt Group Plc - Managers' Transactions____________________________________________Person subject to the notification requirementName: Tuukka TurunenPosition: Other senior managerIssuer: Qt Group PlcLEI: 743700GO2XU2ZYYDKW67Notification type: INITIAL NOTIFICATIONReference number: 75100/4/4 ____________________________________________Transaction date: 2024-08-21Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000198031Nature of transaction: DISPOSAL  Transaction details(1):

EQT INFRASTRUCTURE VI, THROUGH OTELLO BIDCO AB, HAS OBTAINED ALL NECESSARY REGULATORY APPROVALS AND ANNOUNCES ADDITIONAL ACQUISITIONS SECURING 70.12 PERCENT OF THE SHARES IN OX2 AB (PUBL)

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Research from Karolinska University Hospital Reveals New Findings on Women's Fertility

New discoveries about follicles, the cell pouches in women's ovaries, may be important for future treatment of infertility.A new study from Karolinska University Hospital shows that there are two types of immature follicles in a woman's ovaries, and that they probably have different tasks. According to the researchers, only one type of follicle is involved in developing eggs. The other seems instead to be entirely devoted to secreting hormones, a process called signaling. The discovery may have an impact on how we assess female fertility in the future and how we treat involuntary

Notification of major holding in Kindred Group plc

Kindred Group plc (Kindred) hereby announces that it, on 21 August 2024, has received a notification of major holding from The Goldman Sachs Group, Inc., a company with its registered office in Wilmington, USA. The notification refers to a decrease in the number of shares and voting rights in Kindred held by The Goldman Sachs Group.According to the notification, the Goldman Sachs Group held 0.16% of the shares and voting rights in Kindred as of 16 August 2024. The relevant chain of controlled undertakings can be found in the notification, of which a copy can be found on Kindred’s website:

Borr Drilling Limited – Adjustment conversion price convertible bonds

Hamilton, Bermuda, August 22, 2024 Reference is made to Borr Drilling Limited’s (“Borr Drilling” or the “Company”) (NYSE and OSE: ”BORR”) stock exchange releases related to the distribution to shareholders of $0.10 per share as announced on August 14, 2024 (the “Dividend”).  In accordance with the loan agreement for the Company's USD 250,000,000 5% Senior Unsecured Convertible Bonds 2023/2028, ISIN NO0012828187, the Dividend has triggered an adjustment to the conversion price from USD 7.1347 to USD 7.0249 per share.

Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain

Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)[1] heterozygotes or non-carriers.[2] Lecanemab becomes the first the medicine which targets an underlying cause of the disease, to be authorized in a

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B82YXW83 Issuer Name VESUVIUS PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name BlackRock, Inc. City of registered office (if applicable) Wilmington Country of registered office (if applicable) USA 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above   City

NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options

Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours, with the highest accuracy on the market. NADMED provides crucial information on vitamin B3 deficiencies, which have been linked to degenerative age-related diseases such as metabolic diseases, cancer, neurodegenerative and heart diseases.HELSINKI, Finland (August 22nd, 2024) Finnish biotech company NADMED  has closed a €3.5M series A round to fund its entry into the U.S. and other international

Invitation to monthly digital events and presentations of quarterly reports

Hamlet BioPharma is pleased to announce the continuation of the digital event series this autumn. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during the Q&A sessions that will follow each presentation. Please visit our web page to join the digital events: https://hamletbiopharma.com/series-of-digital-events-2024/   The digital event are scheduled for: · September 18th, 2024, 12:00 CET · October 23rd, 2024, 12:00 CET · December 11th, 2024, 12:00 CET   Additionally, please

Novel AI algorithm assists in breast cancer screening

Researchers at the University of Eastern Finland have developed a novel artificial intelligence based algorithm, MV-DEFEAT, to improve mammogram density assessment. This development holds promise for transforming radiological practices by enabling more precise diagnoses. High breast tissue density is associated with an increased risk of breast cancer, and breast tissue density can be estimated from mammograms. The accurate assessment of mammograms is crucial for effective breast cancer screening, yet challenges such as variability in radiological evaluations and a global shortage of

Arctic Bioscience – Invitation to presentation of half year 2024 results

Arctic Bioscience will publish its financial results for the first half year of 2024 on Thursday 29[th] of August, at 08:00 CET.The same day at 11:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Thursday 29[th] of August 2024 Time: 11:00 CET Format: Webcast and Q&A Language: English The presentation can be accessed through the Company’s website, or with the link below: Link: https://channel.royalcast.com/landingpage/

Webstep ASA: Exercise window for share options

Oslo, 22 August 2024: With reference to the stock exchange announcement by Webstep ASA (the “Company”) of 18 November 2019, in which it was announced that Webstep ASA granted employee share options as part of the Company’s long-term incentive programme (“LTIP”).The Company will conduct a window on 28 August - 29 August 2024, in which the option holders may exercise share options. The total amount of vested options is 529,621 options, of which 341,151 options are in the money as of 21 August 2024 and exercisable for the option holders.

Allgon Welcomes Claes Seth as its New CTO

After 17 years of service since 2007 at Tele Radio and Allgon, Jesper Ribbe has decided to leave Allgon by the end of 2024. Jesper played a key role in the success of both organizations, at steering wheel of the technology and R&D departments.Claes Seth will take over the position of Chief Technology Officer, bringing in a plethora of experience in Research & Development in senior positions. Coupled to this experience, Claes also brings a proven record of wireless technologies, telecommunications, embedded software & systems, and team leadership & development to the table at Allgon’s senior

There are no items matching the current filter
There are no more items matching the current filter
Back to top